Sanofi
- Country
- 🇫🇷France
- Ownership
- Public
- Employees
- 87.9K
- Market Cap
- $141.3B
- Website
- http://www.sanofi.com
- Introduction
Sanofi engages in the research, production, and distribution of pharmaceutical products. It operates through the following business segments: Pharmaceuticals, Consumer Healthcare, and Vaccines. The Pharmaceuticals segment comprises the commercial operations of the following global franchises: specialty care, diabetes and cardiovascular, established prescription products and generics, and research, development, and production activities. The Consumer Healthcare segment includes the commercial operations for its Consumer Healthcare products. The Vaccines segment consists commercial operations of Sanofi Pasteur. The company was founded in 1973 and is headquartered in Paris, France.
Evaluation of Insulin Glargine/Lixisenatide Fixed Ratio Combination in Patients With Type 2 Diabetes Insufficiently Controlled With Oral Antidiabetic Drug(s)
- Conditions
- Type 2 Diabetes Mellitus
- Interventions
- Drug: Insulin glargine/Lixisenatide (HOE901/AVE0010)Drug: Insulin glargine (HOE901)Drug: SGLT2 inhibitor
- First Posted Date
- 2019-01-09
- Last Posted Date
- 2022-07-19
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 878
- Registration Number
- NCT03798054
- Locations
- 🇨🇳
Investigational Site Number 1560013, Shanghai, China
🇨🇳Investigational Site Number 1560004, Shanghai, China
🇨🇳Investigational Site Number 1560029, Shanghai, China
Efficacy and Safety of Alogliptin vs. Acarbose in Chinese Type 2 Diabetes Mellitus (T2DM) Patients With High CV Risk or CHD Treated With Aspirin and Inadequately Controlled With Metformin Monotherapy or Drug Naive
- Conditions
- Type 2 Diabetes Mellitus
- Interventions
- First Posted Date
- 2019-01-07
- Last Posted Date
- 2022-04-25
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 1293
- Registration Number
- NCT03794336
- Locations
- 🇨🇳
CHINA, China, China
Efficacy and Safety Study of Dupilumab in Patients With Persistent Asthma
- Conditions
- Asthma
- Interventions
- Drug: PlaceboDrug: Asthma Controller Therapies (include prednisone/prednisolone)Drug: Asthma Reliever Therapies
- First Posted Date
- 2018-12-20
- Last Posted Date
- 2022-12-28
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 486
- Registration Number
- NCT03782532
- Locations
- 🇮🇳
Investigational Site Number :3560009, Pune, India
🇨🇳Investigational Site Number :1560025, Chongqing, China
🇨🇳Investigational Site Number :1560004, Guangzhou, China
A Bioequivalence Study Testing Two Formulations of Sotagliflozin in Healthy Male and Female Subjects Under Fasted Conditions
- Conditions
- Type 2 Diabetes MellitusHealthy Subjects
- Interventions
- First Posted Date
- 2018-12-14
- Last Posted Date
- 2022-04-25
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 66
- Registration Number
- NCT03776227
- Locations
- 🇺🇸
Investigational Site Number 8400001, Miami, Florida, United States
Efficacy and Safety of Efpeglenatide Versus Placebo in Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin Alone or in Combination With Sulfonylurea
- Conditions
- Type 2 Diabetes Mellitus
- Interventions
- Drug: Placebo
- First Posted Date
- 2018-12-10
- Last Posted Date
- 2021-12-02
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 312
- Registration Number
- NCT03770728
- Locations
- 🇺🇸
Investigational Site Number 8400035, Chandler, Arizona, United States
🇺🇸Investigational Site Number 8400005, Glendale, Arizona, United States
🇺🇸Investigational Site Number 8400056, Tucson, Arizona, United States
A Study of Isatuximab-based Therapy in Participants With Lymphoma
- First Posted Date
- 2018-12-07
- Last Posted Date
- 2023-10-17
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 58
- Registration Number
- NCT03769181
- Locations
- 🇰🇷
Investigational Site Number :4100001, Gangnam-gu, Seoul-teukbyeolsi, Korea, Republic of
🇪🇸Investigational Site Number :7240003, Barcelona, Barcelona [Barcelona], Spain
🇫🇷Investigational Site Number :2500007, Pessac, France
Study Comparing the Efficacy and Safety of Insulin Glargine (Basal Insulin)/Lixisenatide (GLP-1 Receptor Agonist) Combination (Soliqua™) in Patients With Type 2 Diabetes Mellitus (T2DM)
- Conditions
- Type 2 Diabetes Mellitus
- Interventions
- Drug: INSULIN GLARGINE/LIXISENATIDE HOE901/AVE0010
- First Posted Date
- 2018-12-06
- Last Posted Date
- 2022-04-25
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 265
- Registration Number
- NCT03767543
- Locations
- 🇨🇦
Investigational Site Number 1240030, Greenfield Park, Canada
🇨🇦Investigational Site Number 1240018, Montreal, Canada
🇨🇦Investigational Site Number 1240029, Montreal, Canada
Evaluation of the Efficacy and Safety of Insulin Glargine 300 U/mL in Patients With Type 2 Diabetes Mellitus Uncontrolled on Other Kinds of Insulin
- First Posted Date
- 2018-12-03
- Last Posted Date
- 2022-04-25
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 372
- Registration Number
- NCT03760991
- Locations
- 🇦🇷
Investigational site Argentina, Buenos Aires, Argentina
🇪🇬investigational site Egypt, Egypt, Egypt
🇮🇳investigational site INDIA, India, India
Efficacy and Safety of Sotagliflozin Versus Placebo in Chinese Patients With Type 2 Diabetes Mellitus Not Adequately Controlled by Diet and Exercise
- Conditions
- Type 2 Diabetes Mellitus
- Interventions
- Drug: placebo
- First Posted Date
- 2018-12-03
- Last Posted Date
- 2022-04-25
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 276
- Registration Number
- NCT03760965
- Locations
- 🇨🇳
Investigational Site Number 1560035, Wuhan, China
🇨🇳Investigational Site Number 1560033, Guangzhou, China
🇨🇳Investigational Site Number 1560014, Huai'An, China
Efficacy and Safety of Sotagliflozin Versus Placebo in Chinese Patients With Type 2 Diabetes Mellitus Not Adequately Controlled by Metformin With or Without Sulfonylurea
- Conditions
- Type 2 Diabetes Mellitus
- Interventions
- First Posted Date
- 2018-12-03
- Last Posted Date
- 2022-04-25
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 377
- Registration Number
- NCT03761134
- Locations
- 🇨🇳
Investigational Site Number 1560039, Baotou, China
🇨🇳Investigational Site Number 1560028, Dalian, China
🇨🇳Investigational Site Number 1560040, Baotou, China